ArticleCNS neuroscience & therapeutics2020
Progressive brain atrophy in Parkinson's disease patients who convert to mild cognitive impairment.
Article in CNS neuroscience & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Traditional Chinese exercise for quality of life, cognition, sleep in Parkinson's disease: a systematic review and meta-analysis.Frontiers in psychology · 2026Pooled it
- Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies.CNS neuroscience & therapeutics · 2021Pooled it
- Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease.Frontiers in neurology · 2021Pooled it
- The effect of Apolipoprotein E4 on cognitive function in Parkinson's disease: A structural MRI study in the PPMI cohort.PloS one · 2026Article
- Entorhinal cortex atrophy mediates the association of plasma p-tau181, GFAP, and NfL with cognitive impairment in Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Classification of Parkinson's disease with and without dopaminergic deficiency based on non-motor symptoms and structural neuroimaging.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Review
- Vitamin D-linked vulnerability and functional connectivity alterations in the superior frontal gyrus contributing to cognitive impairment in Parkinson's disease.Frontiers in aging neuroscience · 2025Article
- Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: gray matter and white matter damage.Frontiers in neurology · 2025Article
- Enhancing early Parkinson's disease detection through multimodal deep learning and explainable AI: insights from the PPMI database.Scientific reports · 2024Article
- Predicting the occurrence of mild cognitive impairment in Parkinson's disease using structural MRI data.Frontiers in neuroscience · 2024Article
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease.NPJ Parkinson's disease · 2023Article
- A multiple-tissue-specific magnetic resonance imaging model for diagnosing Parkinson's disease: a brain radiomics study.Neural regeneration research · 2022Article
- Interactions between cigarette smoking and cognitive status on functional connectivity of the cortico-striatal circuits in individuals without dementia: A resting-state functional MRI study.CNS neuroscience & therapeutics · 2022Article
- Morphological basis of Parkinson disease-associated cognitive impairment: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Characterizing mild cognitive impairment in prodromal Parkinson's disease: A community-based study in China.CNS neuroscience & therapeutics · 2022Article
- Altered Prefrontal Blood Flow Related With Mild Cognitive Impairment in Parkinson's Disease: A Longitudinal Study.Frontiers in aging neuroscience · 2022Article
- Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson's Disease: Current View.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCognitive impairment is a common symptom in the trajectory of Parkinson's disease (PD). However, the pathological underpinning is not fully known. We aimed to explore the critical structural alterations in the process of cognitive decline and its relationships with the dopaminergic deficit and the level of related cerebrospinal fluid (CSF) proteins.
methodsNinety-four patients with PD and 32 controls were included in this study. Neuropsychological tests were performed at baseline and after 28 months to identify which patients had normal cognition and which ones developed PD-MCI after follow-up ("converters"). Gray matter atrophy was assessed in cross-sectional and longitudinal analyses, respectively. The associations between altered GMV with dopamine transporter (DAT) results and the level of CSF proteins were assessed.
resultsAmong the 94 patients with normal cognition at baseline, 24 (mean age, 63.1 years) developed PD-MCI after 28 months of follow-up, and 70 (mean age, 62.3 years) remained nonconverters. The converters showed significant right temporal atrophy at baseline and extensive atrophy in temporal lobe at follow-up. Progressive bilateral frontal lobe atrophy was found in the converters. Baseline right temporal atrophy was correlated with the striatal dopaminergic degeneration in the converters. No correlation was found between the right temporal atrophy and the alterations of CSF proteins.
conclusionEarly atrophy in temporal lobes and progressive atrophy in frontal lobes might be a biomarker for developing multidomain impairment of cognition and converting to PD-MCI. Furthermore, cognition-related temporal atrophy might be associated with dopaminergic deficit reflected by DAT scan but independent of CSF proteins in patients with PD who convert to PD-MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.